stoxline Quote Chart Rank Option Currency Glossary
  
Nuvalent, Inc. (NUVL)
75.09  -1.55 (-2.02%)    03-28 16:00
Open: 75.34
High: 76.2
Volume: 682,409
  
Pre. Close: 76.64
Low: 73.8575
Market Cap: 4,811(M)
Technical analysis
2024-03-28 4:53:16 PM
Short term     
Mid term     
Targets 6-month :  97.47 1-year :  104.4
Resists First :  83.45 Second :  89.38
Pivot price 80.38
Supports First :  73.85 Second :  61.44
MAs MA(5) :  76.3 MA(20) :  81.36
MA(100) :  74.39 MA(250) :  55.67
MACD MACD :  -1.7 Signal :  -0.8
%K %D K(14,3) :  7.4 D(3) :  7.6
RSI RSI(14): 38.1
52-week High :  89.38 Low :  23.09
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NUVL ] has closed above bottom band by 17.6%. Bollinger Bands are 59.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 76.42 - 76.84 76.84 - 77.18
Low: 72.56 - 73.15 73.15 - 73.64
Close: 74.2 - 75.1 75.1 - 75.82
Company Description

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 29 Mar 2024
Matthew Shair Sells 37500 Shares of Nuvalent, Inc. (NASDAQ:NUVL) Stock - Defense World

Fri, 29 Mar 2024
Nuvalent (NASDAQ:NUVL) Shares Down 2% on Insider Selling - Defense World

Wed, 27 Mar 2024
Nuvalent, Inc. (NASDAQ:NUVL) Director Sells $2,878,875.00 in Stock - MarketBeat

Tue, 26 Mar 2024
Nuvalent, Inc. (NASDAQ:NUVL) Insider Darlene Noci Sells 20000 Shares - Defense World

Mon, 25 Mar 2024
Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL) - Yahoo Finance

Mon, 25 Mar 2024
Nuvalent executive sells over $1.5m in company stock By Investing.com - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 59 (M)
Shares Float 29 (M)
Held by Insiders 3.8 (%)
Held by Institutions 110.3 (%)
Shares Short 6,540 (K)
Shares Short P.Month 6,300 (K)
Stock Financials
EPS -2.18
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.93
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -15.4 %
Return on Equity (ttm) -21.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -100 (M)
Levered Free Cash Flow -56 (M)
Stock Valuations
PE Ratio -34.61
PEG Ratio 0
Price to Book value 6.86
Price to Sales 0
Price to Cash Flow -44.15
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android